Latest Ratios: P/E Ratio 53.8x · EV/EBITDA 38.5x · ROE 101.2%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.17T | $965.1B | $697.9B | $526.5B | $347.6B | $263.4B | $161.5B | $125.8B | $119.6B | $88.9B | $81.0B |
| Enterprise Value | $1.20T | $1.00T | $728.3B | $548.9B | $361.8B | $276.5B | $174.4B | $139.3B | $122.6B | $96.0B | $86.7B |
| P/E Ratio → | 53.84 | 46.83 | 65.93 | 100.50 | 55.68 | 47.22 | 26.10 | 15.12 | 36.97 | — | 29.54 |
| P/S Ratio | 17.91 | 14.81 | 15.49 | 15.43 | 12.18 | 9.30 | 6.58 | 5.64 | 5.57 | 4.45 | 3.82 |
| P/B Ratio | 41.81 | 36.37 | 48.90 | 48.47 | 32.26 | 28.77 | 27.73 | 46.63 | 10.96 | 7.62 | 5.75 |
| P/FCF | 130.11 | 107.56 | 1684.61 | — | 75.56 | 48.89 | 36.13 | 36.13 | 47.73 | 25.74 | 21.54 |
| P/OCF | 69.43 | 57.40 | 79.15 | 124.18 | 45.82 | 35.76 | 24.85 | 26.02 | 21.65 | 15.82 | 16.69 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 15.35 | 16.17 | 16.09 | 12.68 | 9.76 | 7.11 | 6.24 | 5.70 | 4.80 | 4.09 |
| EV / EBITDA | 38.48 | 32.00 | 37.80 | 44.58 | 35.55 | 29.16 | 20.44 | 19.26 | 16.06 | 16.50 | 16.15 |
| EV / EBIT | 40.50 | 37.93 | 54.11 | 77.97 | 50.68 | 42.57 | 22.99 | 24.59 | 31.25 | 37.93 | 24.36 |
| EV / FCF | — | 111.50 | 1757.93 | — | 78.64 | 51.32 | 39.02 | 40.00 | 48.91 | 27.80 | 23.06 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 83.8% | 83.8% | 81.3% | 79.2% | 76.8% | 74.2% | 77.7% | 78.8% | 78.2% | 77.7% | 73.1% |
| Operating Margin | 45.6% | 45.6% | 38.9% | 31.6% | 30.3% | 28.0% | 29.4% | 26.9% | 28.0% | 21.3% | 18.2% |
| Net Profit Margin | 31.7% | 31.7% | 23.5% | 15.4% | 21.9% | 19.7% | 25.2% | 37.3% | 15.0% | -1.0% | 12.9% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 101.2% | 101.2% | 84.3% | 48.4% | 62.7% | 74.5% | 145.3% | 122.3% | 28.6% | -1.6% | 19.1% |
| ROA | 21.6% | 21.6% | 14.8% | 9.2% | 12.7% | 11.7% | 14.4% | 20.0% | 7.3% | -0.5% | 7.4% |
| ROIC | 41.8% | 41.8% | 33.7% | 27.8% | 27.5% | 29.0% | 31.0% | 29.9% | 27.7% | 16.5% | 15.0% |
| ROCE | 46.6% | 46.6% | 40.2% | 31.2% | 26.2% | 23.4% | 23.4% | 20.2% | 19.3% | 14.6% | 14.0% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.60 | 1.60 | 2.36 | 2.32 | 1.51 | 1.84 | 2.85 | 5.86 | 0.94 | 1.17 | 0.73 |
| Debt / EBITDA | 1.36 | 1.36 | 1.75 | 2.05 | 1.60 | 1.78 | 1.94 | 2.19 | 1.35 | 2.35 | 1.92 |
| Net Debt / Equity | — | 1.33 | 2.13 | 2.06 | 1.32 | 1.43 | 2.22 | 4.99 | 0.27 | 0.61 | 0.41 |
| Net Debt / EBITDA | 1.13 | 1.13 | 1.58 | 1.82 | 1.39 | 1.38 | 1.52 | 1.86 | 0.39 | 1.22 | 1.07 |
| Debt / FCF | — | 3.94 | 73.32 | — | 3.08 | 2.43 | 2.89 | 3.87 | 1.19 | 2.06 | 1.52 |
| Interest Coverage | 33.16 | 33.16 | 17.24 | 14.49 | 21.53 | 19.12 | 21.11 | 14.15 | 16.18 | 11.24 | 19.22 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.58 | 1.58 | 1.15 | 0.94 | 1.05 | 1.23 | 1.40 | 1.16 | 1.73 | 1.32 | 1.37 |
| Quick Ratio | 1.19 | 1.19 | 0.89 | 0.73 | 0.80 | 0.97 | 1.08 | 0.89 | 1.47 | 1.01 | 1.05 |
| Cash Ratio | 0.21 | 0.21 | 0.12 | 0.11 | 0.13 | 0.26 | 0.29 | 0.21 | 0.62 | 0.55 | 0.55 |
| Asset Turnover | — | 0.58 | 0.57 | 0.53 | 0.58 | 0.58 | 0.53 | 0.57 | 0.49 | 0.44 | 0.55 |
| Inventory Turnover | 0.77 | 0.77 | 1.11 | 1.23 | 1.54 | 1.88 | 1.38 | 1.48 | 1.51 | 1.00 | 1.60 |
| Days Sales Outstanding | — | 112.87 | 107.58 | 121.25 | 109.45 | 104.75 | 103.06 | 90.62 | 98.10 | 96.16 | 81.98 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 0.5% | 0.6% | 0.7% | 0.8% | 1.0% | 1.2% | 1.7% | 1.9% | 1.9% | 2.5% | 2.7% |
| Payout Ratio | 26.1% | 26.1% | 44.2% | 77.7% | 56.6% | 55.3% | 43.4% | 29.0% | 71.5% | — | 78.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 1.9% | 2.1% | 1.5% | 1.0% | 1.8% | 2.1% | 3.8% | 6.6% | 2.7% | — | 3.4% |
| FCF Yield | 0.8% | 0.9% | 0.1% | — | 1.3% | 2.0% | 2.8% | 2.8% | 2.1% | 3.9% | 4.6% |
| Buyback Yield | 0.4% | 0.4% | 0.4% | 0.1% | 0.4% | 0.5% | 0.3% | 3.5% | 3.5% | 0.3% | 0.7% |
| Total Shareholder Yield | 0.8% | 1.0% | 1.0% | 0.9% | 1.4% | 1.6% | 2.0% | 5.4% | 5.4% | 2.8% | 3.4% |
| Shares Outstanding | — | $898M | $904M | $903M | $950M | $954M | $957M | $958M | $1.0B | $1.1B | $1.1B |
Manufacturing capacity bottleneck risks
Based on reported figures, LLY trades at a forward P/E of 32.97, which significantly exceeds the broader pharmaceutical index and suggests that investors are pricing the company as a high-growth technology firm rather than a traditional, value-oriented drug manufacturer with slower, more predictable long-term revenue trajectories.
The current P/S ratio of 17.49 indicates that the market is assigning a substantial premium to Lilly's metabolic pipeline, specifically the tirzepatide franchise. This valuation appears to hinge on the assumption of sustained, outsized growth, which warrants caution should future regulatory pricing pressures or competitive supply chain dynamics temper these aggressive market expectations.
According to recent financial statements, LLY's ROIC has fluctuated between 5.9% and 11.3% over the last ten quarters, reflecting the heavy capital intensity required to build out proprietary manufacturing capacity for its incretin platform, which temporarily suppresses returns compared to less asset-heavy, legacy pharmaceutical business models.
While the ROE has shown periods of strength, reaching 33.1% in 2025Q2, the underlying ROIC suggests that the company is currently in a phase of significant capital deployment. Investors should monitor whether these investments in sterile fill-finish facilities eventually yield the expected compounding returns as the metabolic portfolio reaches full global scale.
As reported in quarterly data, LLY's cash conversion cycle reached 319 days in 2026Q1, a trend driven by high inventory levels and extended receivables that suggests the company is prioritizing supply chain readiness over immediate cash flow optimization during this period of rapid global product expansion.
The elevated DIO of 356 days highlights the strategic decision to maintain significant inventory buffers to mitigate potential supply shortages for high-demand metabolic drugs. This operational approach, while necessary for market share capture, creates a structural drag on liquidity that distinguishes Lilly's current working capital profile from more mature, stable-growth peers.
Based on recent SEC filings, LLY's current ratio has hovered between 0.94 and 1.58, indicating that while the company maintains sufficient liquidity to meet short-term obligations, its cash position remains lean relative to the massive, ongoing capital expenditures required for its global manufacturing and R&D initiatives.
The quick ratio, which bottomed at 0.73 in 2023Q4, suggests that the company is heavily reliant on inventory turnover to maintain its liquidity position. This reliance implies that any disruption in the supply chain or a sudden shift in demand could place temporary pressure on the company's ability to fund its aggressive growth strategy without external financing.
As noted in industry analysis, the P/E ratio is frequently misapplied to LLY because it fails to account for the lumpy nature of milestone payments and the massive, non-recurring capital expenditures currently distorting earnings, making it a poor proxy for the company's underlying cash-generating potential and long-term value.
Investors should instead focus on adjusted free cash flow or EV/EBITDA, which better capture the company's ability to convert its high-margin revenue into sustainable capital. Relying solely on P/E may obscure the significant margin expansion potential that could emerge once the current phase of heavy infrastructure investment concludes.
Includes 30+ ratios · 30 years · Updated daily
Wall Street verdict, signals, and target summaries.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying LLY stock.
Eli Lilly and Company's current P/E ratio is 53.8x. The historical average is 32.4x. This places it at the 89th percentile of its historical range.
Eli Lilly and Company's current EV/EBITDA is 38.5x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 19.1x.
Eli Lilly and Company's return on equity (ROE) is 101.2%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 41.8%.
Based on historical data, Eli Lilly and Company is trading at a P/E of 53.8x. This is at the 89th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Eli Lilly and Company's current dividend yield is 0.49% with a payout ratio of 26.1%.
Eli Lilly and Company has 83.8% gross margin and 45.6% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
Eli Lilly and Company's Debt/EBITDA ratio is 1.4x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.